Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NuVasive

This article was originally published in The Gray Sheet

Executive Summary

Privately held maker of minimally invasive spinal surgery systems raises $29.3 mil. in an equity financing led by William Blair Capital Partners, firm reports May 21. Proceeds will be used to support the launch of the company's recently approved products, including the INS-1 intraoperative nerve surveillance system, which gained 510(k) clearance in November 2000 (1"The Gray Sheet" Dec. 11, 2000, p. 22). The San Diego company's other products include SpineArc surgical guide frame and the Vector cannulae for less traumatic access to the spine. Other investors included Sofinov and Kleiner Perkins Caulfield & Byers

You may also be interested in...



Health And Wellness Product Trademark Review 10 December, 2019

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Expert Panel Affirms ‘Continued Marketing’ Of Ambrisentan, Everolimus In India

Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.

US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector

"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB is adhering to executive order President Trump made earlier in 2019 instructing federal agencies to enforced based on regulations, not on guidance.
UsernamePublicRestriction

Register

MT014969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel